Drug-related Atrioventricular Block: Is It a Benign Condition?

Sima Sayah 1, Mohammad Ali Akbarzadeh 2,3,*, Zahra Emkanjoo 4, Reza Mollazadeh 5, Shahab Shahrzad 4, Negar Bahrololoumi Bafroue 6

1 Cardiology Department, Ghazvin University of Medical Sciences, Ghazvin, Iran
2 Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Department of Cardiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Department of Pacemaker and Electrophysiology, Shaheed Rajaee Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
5 Emamkhomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
6 Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran

* Corresponding author: Mohammad Ali Akbarzadeh. Cardiovascular Research Center, Shahid Modarres Hospital, Saadat Abad Street, Tehran, Iran. Tel: +98-9173171001, E-mail: akbarzadehali@sbmu.ac.ir

Abstract

Introduction: Prognosis of the patients with beta blocker or calcium channel blocker induced AV block is not well known to date.

Methods: All patients with symptomatic second-degree or third-degree atrioventricular block (AV) referred to our institution during one year were recruited prospectively and classified in two groups based on drug consumption (beta blocker/calcium channel blocker versus none). They were followed for six months and then collected data was analyzed.

Results: The study included 49 patients, 28 patients (age 60.1 ± 20, 19 male) did not use any beta blocker or calcium channel blocker (No-DU group) and other 21 patients (age 73.5 ± 10.4, 7 male) received beta blocker, calcium channel blocker or both at the time of AV block (DU group). No-DU group was significantly younger than DU group. The most common atrial rhythm in both groups was sinus. There was no significant difference in QRS wideness or ventricular rate. AV block regressed in 43% of the DU group after discontinuation of drug for five half-life, but, Mobitz type 2 or complete AV block occurred again during six months in 50% of them without consumption of the culprit drug.

Conclusions: More than two third of the patients who developed AV block on beta blocker and/or calcium channel blocker needed permanent pacemaker in six months of follow-up, so we concluded that the development of AV block was not as benign as it seems in these patients.

INTRODUCTION

According to ACC/AHA/HRS 2008 Guideline, permanent pacemaker implantation is indicated for third degree and advanced second-degree atrioventricular block (AV) at any anatomic level associated with symptomatic bradycardia or ventricular arrhythmias presumed to be due to AV block and also is indicated in symptom-free patients in sinus rhythm, with documented periods of asystole greater than or equal to 3.0 seconds, any escape rate less than 40 beat per minute (bpm), or with an escape rhythm that is below the AV node (class I) [1]. However, pacemaker implantation is generally considered unnecessary if it caused by reversible etiologies such as electrolyte abnormalities [1].

It is documented that drugs such as calcium channel blockers and beta blockers, prolong AV nodal conduction and refractoriness in humans may cause AV block [2, 3]. But since the significant bradycardia is rare with therapeutic doses in normal heart [4], one of the theories can be unmasking of underlying AV node or hiss-purkinje diseases caused by these medications. So prognosis and natural history of the patients with drug related AV block need to be investigated.
METHODS
This prospective study was designed for assessment of midterm prognosis in patients with drug induced AV block. The study protocol was reviewed, and approved by the Review Board of Shaheed Rajaei Cardiovascular Medical and Research Center, and Iran University of Medical Sciences High Research Council. All patients with symptomatic second-degree or third-degree AV block referring to our institution between April 2010 and April 2011 were prospectively collected. Patients with concomitant myocardial infarction, electrolyte abnormalities, digitalis toxicity, vasovagal syncope, and those taking class I or III antiarrhythmics were excluded.

The type of AV block was determined by the surface electrocardiogram (ECG). Patients were classified into two groups to define a relationship between beta-blocker or calcium channel blocker therapy and AV block: (1) patients who developed AV block in the absence of drugs that affect AV conduction (No-DU group), (2) patients in whom AV block occurred on beta-blockers or calcium channel blockers therapy (DU group).

Patients in group 2 were subclassified as follows: (1) patients in whom AV block resolved after the discontinuation of drug after 5 half-life (Soon-AVB-R) (2) patients in whom AV block was not resolved and persisted in spite of discontinuation of drug (Soon-AVB-NR).

All patients were monitored continuously during their hospitalization course until they had improved AV conduction within 4-6 days or received an implanted pacemaker (if AV block did not resolve). Patients with apparently normal AV conduction after discontinuation of drug, were discharged and recommended to visit arrhythmia clinic, for evaluation of AV conduction with surface ECG. Patients who had pacemaker placement have been followed in pace maker clinic on a regular basis.

Permanent pacemaker was implanted for all of the patients with recurrence of AV block during follow-up. Collection and analysis of data were authorized by the ethics committee of the hospital. Data were expressed as mean ± SD. Student’s T test, Chi square test and Fisher’s exact probability test were used to analyze the data. Results were considered significant at an error probability level of P < 0.05.

RESULTS
Twenty eight of 49 patients who met the criteria and entered the study, didn’t use any beta blocker or calcium channel blocker (No-DU group). Mean age of this group was 60.1 ± 20 years, 32.1% were female and 67.9% were male (Table 1). Other 21 patients with mean age of 73.5 ± 10.4 years (66.7% female; 33.3% male) were receiving beta blocker (81%), calcium channel blocker (9.5%) or both (9.5%) at the time of AV block (DU group). This group was significantly older than No-DU group (P = 0.04) and dominantly was female (P = 0.02) (Table 1).

Although Sinus rhythm was the most common atrial rhythm in both No-DU and DU patients (92.9% and 95.2%, respectively), the degree of AV block seemed to be some what different in both groups. In No-DU group, no patient had Mobitz type I (Wenckebach) AV block, 7.1% had Mobitz type 2, and 92.9% had third degree AV block compared to 4.8, 33.3 and 61.9 in DU group, respectively. QRS duration and also ventricular rate were not significantly different between both groups (Table 1).

Follow-up after Five Half Life of Drug
AV block regressed in 43% (9 of 21) of the DU patients with discontinuation of drug after 5 half-life (Soon-AVB-R). Mean age of this subgroup was 69.7 ± 10 years (55.6% female; 44.4% male).The remained 57% patients whose AV blocks persist in spite of discontinuation of drug (Soon-AVBNR) candidate for permanent pacemaker implantation. The mean age of this subgroup was 76.4 ± 10 years (75% female; 25% male) which was not significantly different from previous subgroup. Analysis of these two subgroups didn’t show any significant differences in degree of AV block, QRS duration, and ventricular rate (Table 2).

<table>
<thead>
<tr>
<th>Table 1: Comparison Between the Patients Who Were on Medication and Who Weren’t on Medication at the Time of Atrioventricular Block</th>
</tr>
</thead>
<tbody>
<tr>
<td>AV Block During Drug Therapy, (n = 21)</td>
</tr>
<tr>
<td>Age (y)</td>
</tr>
<tr>
<td>Male Gender</td>
</tr>
<tr>
<td>Sinus rhythm</td>
</tr>
<tr>
<td>Level of block</td>
</tr>
<tr>
<td>Wenckebach</td>
</tr>
<tr>
<td>Mobitz type 2</td>
</tr>
<tr>
<td>Complete AV block</td>
</tr>
<tr>
<td>QRS duration &gt; 120 msec</td>
</tr>
<tr>
<td>Ventricular rate &lt; 40 bpm</td>
</tr>
</tbody>
</table>

Data are presented as mean ± SD and No. (%).
A Six-month Follow-up

In a six-month follow-up, one of the cases missed, in Soon-AVB-R group, 50% developed Mobitz type 2 or complete AV block that needed permanent pacemaker implantation. On the other side, 8.3% (one case) of the Soon-AVB-NRs in the absence of drug therapy (with betablocker and/or calcium channel blocker) and 3.6% (one case) of No-DUs showed disappearance of AV block and restoration of sinus rhythm in follow up. (Table 3)

If we pool all the patients with AV block during drug consumption who needed permanent pacemaker implantation till six months of follow-up as drug users, not drug related AV block group (DU-NDR), and who didn’t need permanent pacemaker implantation as drug users, drug related group (DU-DR), and compare them, again there will be no significant differences according to QRS duration or ventricular rate.

DISCUSSION

In our study, most of the patients with AV block in No-DU was male, but most of the patients in DU was female. This can be concluded that increasing female consuming beta blockers or calcium channel blocker or these kinds of drugs results in increasing AV blocks. However, the main finding of our study was that nearly one half of the patients admitted in the hospital due to AV block (except those caused by digoxin toxicity, myocardial infarction, electrolyte imbalance and vasovagal response) was on beta blocker and/or calcium channel blocker. Drugs were discontinued in all of these patients, but in 43% of them, AV block didn’t regress, and in 50% of them AV block resolved, relapse was seen in less than six months. So it seems that about 70% of patients who was on beta blocker and/or calcium channel blocker at the time of AV block, permanent pacemaker was needed in six months of follow-up.

There are few other studies with the same result [5, 6]. A recent study reported that only 15% of AV blocks in patients treated with beta-blockers and/or calcium channel blocker, is truly caused by these drugs and in others, drug was only ‘innocent bystanders’ [5]. The authors concluded that as the effect of these drugs is slowing down the conduction of SA node and AV node and this would decrease conduction block in infra- nodal pathways, so in these patients, infra- nodal conduction disease expected to be more severe. In our study, we couldn’t find any relationship between QRS duration or ventricular rate (as signs of supranodal or infra -nodal disease) [7-9] and AV block in drug users; in other word, ECG finding of supra or infra nodal block is not a predictor of permanent pacemaker requirement in patients who consumes drug and are on AV block.

Another study that assessed the prognosis of bradycardia related to drugs, evaluated 38 patients with symptomatic bradycardia during beta blocker or calcium channel blocker consumption, and showed that in 10 of 38 cases, bradycardia were not caused by drugs, but were revealed by drugs [10]. Interestingly, in this study, if we omit cases with AV block from that 31 patients who came with symptomatic sinus bradycardia, 27(87%) patients with bradycardia will be resolved by discontinuation of drugs [10].

Comparing these studies, one can argue when a patient referred due to symptomatic bradycardia on beta blocker or calcium channel blockers, if the bradycardia is caused by the second or third degree AV block, it is less probably that the drug induces and if it is caused by sinus bradycardia it is most probably that the drug induces and will regress by discontinuation of drug.

Study limitation: 1) We studied 49 cases prospectively and this limited numbers of patients prevent subgroup analysis. So some important features such as the effect of drug dose,
which may be a predictor of reversibility, were not evaluated in this study. 2) Although most of the clues in this and previous studies are compatible with infra-nodal disease of cases who developed AV block on beta blocker or calcium channel blocker, the studies on electrophysiology is needed.

ACKNOWLEDGEMENTS

The study has been supported by Cardiac Electrophysiology research center, Rajaie Cardiovascular Medical and Research Center, Tehran University of Medical Sciences and Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

CONFLICT OF INTEREST

There is no conflict of interest for the present study.

REFERENCES


